STOCK TITAN

Panbela Therapeutics Inc. - PBLA STOCK NEWS

Welcome to our dedicated news page for Panbela Therapeutics (Ticker: PBLA), a resource for investors and traders seeking the latest updates and insights on Panbela Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Panbela Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Panbela Therapeutics's position in the market.

Rhea-AI Summary
Panbela Therapeutics, Inc. (PBLA) provides a business update and financial results for the quarter and full year ended December 31, 2023. Highlights include collaborations, clinical advancements, financial milestones, and ongoing trials. The company reported a net loss of $6.5 million in Q4 2023, with total cash at $2.6 million as of December 31, 2023. Panbela is focused on the ASPIRE trial for pancreatic cancer and remains committed to maximizing value for shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.44%
Tags
earnings
-
Rhea-AI Summary
Panbela Therapeutics, Inc. (PBLA) to host a conference call to discuss Q4 and year-end 2023 results, focusing on disruptive therapeutics for urgent medical needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
conferences earnings
-
Rhea-AI Summary
Panbela Therapeutics, Inc. (PBLA) regains compliance with Nasdaq listing standards, ensuring continued listing of common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.62%
Tags
none
Rhea-AI Summary
Panbela Therapeutics, Inc. (PBLA) has closed a public offering, raising approximately $9.0 million in gross proceeds. The offering included 4,375,000 shares of common stock or pre-funded warrants and two classes of warrants to purchase up to 8,750,000 shares of common stock. The company intends to use the net proceeds for clinical development, working capital, business development, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.35%
Tags
offering
-
Rhea-AI Summary
Panbela Therapeutics, Inc. (Nasdaq: PBLA) announced that their abstract for SBP-101, a proprietary polyamine analogue, has been accepted for poster presentation at the American Association for Cancer Research (AACR) in April 2024. The abstract reflects the Company’s collaboration with Johns Hopkins University School of Medicine and details the presentation title, session category, session title, date, and time. The abstract and poster will be available on the Company's website once released by AACR.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.46%
Tags
none
-
Rhea-AI Summary
Panbela Therapeutics, Inc. (PBLA) announced a public offering of 4,375,000 shares of its common stock and two classes of warrants to purchase up to 8,750,000 shares at a purchase price of $2.06 per share. The offering is expected to close on a specified date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-65.34%
Tags
offering
Rhea-AI Summary
Panbela Therapeutics, Inc. (Nasdaq: PBLA) has announced reaching 50% enrollment for its ASPIRE global clinical trial for the treatment of metastatic pancreatic cancer. The company expects full enrollment by Q1 2025 and anticipates interim data analysis on overall survival in mid-2024. The trial is a randomized, double-blind placebo-controlled clinical trial to evaluate ivospemin in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. With approximately 90 sites running globally, Panbela aims to deliver a more effective treatment for pancreatic cancer, a deadly disease with limited treatment options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.96%
Tags
none
-
Rhea-AI Summary
Panbela Therapeutics, Inc. (PBLA) announces positive clinical data from a Phase 1 study of high dose DFMO treatment in combination with chemotherapy for neuroblastoma patients. The study showed that DFMO treatment was well tolerated, with a median time-to-progression of 19.8 months. The overall objective response rate was 9%, and the progression-free survival at 2 years was 29.5%. These results suggest that CPP-1X is a safe, oral treatment option that may improve response rates in heavily pretreated relapsed refractory neuroblastoma patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1432.26%
Tags
clinical trial
-
Rhea-AI Summary
Panbela Therapeutics, Inc. (PBLA) announced a 1-for-20 reverse stock split to increase the market price per share and regain compliance with Nasdaq listing requirements. The split will reduce outstanding shares to an estimated 480 thousand and will affect all stockholders uniformly. The company's transfer agent will provide instructions for the exchange of shares, and fractional shares will be paid in cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.92%
Tags
stock split
Rhea-AI Summary
Panbela Therapeutics, Inc. (Nasdaq: PBLA) announces agreements with holders of existing warrants to exercise for 2,556,000 shares of common stock, raising approximately $2.0 million. The exercise of new warrants is subject to stockholder approval. The new warrants will be exercisable for up to 5,112,000 shares of common stock at an exercise price of $0.95 per share and will remain exercisable for up to five years after stockholder approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.58%
Tags
none
Panbela Therapeutics Inc.

OTC:PBLA

PBLA Rankings

PBLA Stock Data

2.35M
256.32k
0.01%
0.6%
3.07%
Biotechnology
Healthcare
Link
US
Waconia